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ABSTRACT
The three-memberedRUNX gene family includesRUNX1, amajormutational target in human leukemias, and displays hallmarks of both tumor
suppressors and oncogenes. In mouse models, the Runx genes appear to act as conditional oncogenes, as ectopic expression is growth
suppressive in normal cells but drives lymphoma development potently when combined with over-expressed Myc or loss of p53. Clues to
underlying mechanisms emerged previously from murine fibroblasts where ectopic expression of any of the Runx genes promotes survival
through direct and indirect regulation of key enzymes in sphingolipid metabolism associated with a shift in the “sphingolipid rheostat” from
ceramide to sphingosine-1-phosphate (S1P). Testing of this relationship in lymphoma cells was therefore a high priority. We find that ectopic
expression of Runx1 in lymphoma cells consistently perturbs the sphingolipid rheostat, whereas an essential physiological role for Runx1 is
revealed by reduced S1P levels in normal spleen after partial Cre-mediated excision. Furthermore, we show that ectopic Runx1 expression
confers increased resistance of lymphoma cells to glucocorticoid-mediated apoptosis, and elucidate the mechanism of cross-talk between
glucocorticoid and sphingolipid metabolism through Sgpp1. Dexamethasone potently induces expression of Sgpp1 in T-lymphoma cells and
drives cell death which is reduced by partial knockdown of Sgpp1with shRNA or direct transcriptional repression of Sgpp1 by ectopic Runx1.
Together these data show that Runx1 plays a role in regulating the sphingolipid rheostat in normal development and that perturbation of this
cell fate regulator contributes to Runx-driven lymphomagenesis. J. Cell. Biochem. 118: 1432–1441, 2017. © 2016 The Authors. Journal of Cellular
Biochemistry Published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
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RUNX1 (AML1) is one of the most frequently affected genes inhuman leukemias where it is subject to mutational processes
including chromosomal translocation, gene amplification, and point
mutation [Osato, 2004; De Braekeleer et al., 2009]. In acute myeloid
leukemias, diverse chromosomal breakage and fusion events result
in truncation of the RUNX1 gene product and deletion or
replacement of the C-terminal transactivation domain with
heterologous sequences. Point mutation with apparent loss of
function or dominant negative activity is a feature of immature M0
AML [Schnittger et al., 2011] suggesting that RUNX1 may act as a
tumor suppressor in this lineage and that the oncogenic fusions
operate primarily by a dominant negative mechanism [De Braekeleer
et al., 2009]. A tumor suppressor role for Runx1 in myeloid leukemia
is also suggested by mouse models where Runx1 deletion is induced,
for example, in Flt3-ITD expressing mice [Mead et al., 2013].
However, the notion thatRUNX1 is simply a suppressor whose loss of
functions confers an automatic growth advantage is challenged by
more recent observations that human leukemia cells bearing the
common RUNX1-ETO fusion cannot tolerate loss of the remaining
wild-type RUNX1 allele [Ben-Ami et al., 2013]. Moreover, although
the frequent TEL-RUNX1 fusion in childhood B-ALL is often
complemented by loss of the wild-type TEL allele, the unaffected
RUNX1 allele is generally intact and is in fact more likely to show
copy number gain [Niini et al., 2000].
Early evidence frommouse models showed that all three members
of the Runx family can act as targets for transcriptional activation in
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retrovirus-induced lymphomas [Stewart et al., 1997, 2002; Wotton
et al., 2002]. Moreover, transgenic over-expression leads to
predisposition to lymphoma and is strongly synergistic with other
oncogenes (Myc, Myb, Pim1) or loss of p53 tumor suppressor
function [Vaillant et al., 1999; Blyth et al., 2001, 2006; Shimizu et al.,
2013; Huser et al., 2014]. Although oncogenic activity has beenmost
extensively documented for Runx2, ectopic expression of Runx1 has
been shown to collaborate strongly with Myc in T and B-cell
lymphomagenesis [Blyth et al., 2009]. Although a small proportion
of primary human T-cell acute lymphoblastic leukemias (ALL) carry
point mutations in RUNX1 [Grossmann et al., 2011], evidence for an
oncogenic role for this gene in childhood B-ALL is suggested by the
high expression of RUNX1 [Niini et al., 2000] and high level
amplification in a poor prognosis subset [Robinson et al., 2003].
These findings reinforce the hypothesis that the Runx gene family
can operate as tumor suppressors or as oncogenes depending on the
context in which misregulation occurs.
Clues to the contextual factors that influence the outcome of Runx
gain or loss have come from studies in mouse and human fibroblasts
where integrity of the p53 pathway determines the response to
ectopic Runx expression. Normal primary fibroblasts undergo
senescence-like growth arrest in response to ectopic Runx expres-
sion, while cells in which the p53 pathway is disabled instead display
enhanced survival and oncogenicity [Wotton et al., 2004; Kilbey
et al., 2007; Wolyniec et al., 2009]. Moreover, ectopic Runx
expression in immortalized Ink4a/Arf null fibroblasts revealed a
novel link between oncogenic transcription factors and sphingolipid
metabolism [Wotton et al., 2008]. Several enzymes involved in
sphingolipid metabolism (Sgpp1, Ugcg, Siat9) were identified as
direct Runx targets and regulated in a manner consistent with
elevated Sphingosine-1-phosphate (S1P) and reduced ceramide
levels, changes which were also confirmed at the biochemical level
[Wotton et al., 2008; Kilbey et al., 2010].
Bioactive lipids mediate many essential roles in normal develop-
ment and disease. S1P is among the best characterized and is
recognized as a regulator of key processes in cancer development
including survival, proliferation, and angiogenesis [Takabe et al.,
2008]. TheprecursorsofS1P, sphingosine, andceramide aremediators
of cell growth arrest and apoptosis [Zhang et al., 1991; Olivera and
Spiegel, 1993; Cuvillier et al., 1996]. Regulation of the balance
between these interconvertible lipids forms the basis of the
sphingolipid rheostat and themeans bywhich ceramide, sphingosine,
andS1Pcontrol cell growthand survival in response to environmental
and cellular cues. Multiple enzymes control the rheostat and the
biochemical processes that generate or degrade its key components
[Van Brocklyn and Williams, 2012]. However, despite the wealth of
literature on the biology and biochemistry of these processes, links
between sphingolipid signaling and cancer gene function, have
emerged only recently [Kilbey et al., 2010; Heffernan-Stroud et al.,
2012; Burns et al., 2013; Kajiwara et al., 2014]. The evidence of Runx
regulation of sphingolipid metabolism in fibroblast survival stimu-
lated our interest in its relevance to lymphomagenesis where there is
strong evidence for an oncogenic role. We examined cell lines from
p53 null and Em-Myc lymphomas where ectopic Runx expression has
been shown to collaborate strongly in oncogenesis [Blyth et al., 2001,
2009]. Our results demonstrate a consistent role for Runx1 in control
of sphingolipid metabolism in lymphomas as well as in normal
development.Moreover,we showthat Runx1 regulates glucocorticoid
sensitivity in lymphoma cells and identify an established direct target
gene, Sgpp1, as an integrator of sphingolipid metabolism and
responses to glucocorticoids.
MATERIALS AND METHODS
GENERATION OF TRANSGENIC MICE AND CELL LINES
MxLoxP mice (Mx1Creþ Runx1fl/fl) were created as previously
described [Borland et al., 2016]. Mx1Cre positive and negative
offspring were treated at seven weeks of age with six injections of
600mg polyinosinic polycytidylic acid (pIpC), or an equivalent
volume of PBS, on alternate days and sacrificed for tissue samples
two days after the final pIpC treatment.
Tumor-prone Runx1-floxed mice carrying the EmMyc transgene
and heterozygous for p53 loss (Mx1CreþRunx1fl/flEmMycþp53þ/)
were created by crossing Mx1CreþRunx1fl/flp53þ/ mice with
Runx1fl/flEmMycþ mice as previously described [Borland et al.,
2016]. Offspring were sacrificed at onset of tumor symptoms and
cells from splenic tumors placed into culture to establish cell lines.
Animal protocols used in this work were evaluated and approved
by the University of Glasgow Ethics and Welfare Committee and
were carried out under Home Office License (approval granted
September 2012, license number PPL 60/4408) as governed by the
Animal Scientific Procedures Act, 1986 and EU Directive 2010.
CELL CULTURE AND TRANSFECTIONS
Cell lines were established from p53/ thymic lymphomas or EmMyc
splenic lymphomas as previously described [Borland et al., 2016].
Transfections were carried out using Superfect Transfection Reagent
(Qiagen, Crawley, UK) according to the manufacturer’s instructions.
Conditions for transfection have been previously described (21). The
3s cell line was derived from an Mx1CreþRunx1fl/flEmMycþp53þ/
tumor treated with andwithout 10U/ml IFNb (R&D systems) for 8 h to
excise Runx1. For growth analyses cells were plated at 5 105/ml (T
cell lymphoma) or 2.5 105/ml (B cell lymphoma) in a12-well plate in
triplicate. Live/dead cell counts were carried out using a hemocytom-
eter and Trypan blue as a vital indicator.
PCR GENOTYPING PROTOCOLS AND PRIMERS
Tissue DNA samples were prepared using the Nucleon Genomic DNA
Extraction Kit. Runx1 primers forWT, floxed and deleted alleles, and
PCR cycling conditions are as described in Chen et al. [2009]. The
PCR products were resolved on a 2.0% TAE agarose gel. Control
DNAs includes Balb/c kidney (WT Runx1) and Mx1Cre Runx1fl/fl
spleen (non-excised floxed Runx1, excised Runx1).
QUANTITATIVE REAL-TIME PCR
Runx1-expressingandcontrol lymphocyteswereplated in triplicate on
6 well plates at 5 106/well in the presence and absence of 1.0mM
dexamethasone for 6 h. RNA extraction and cDNA preparation were
performed as described (21). For quantitative real-time PCR, 12.5 ng
aliquots of cDNAwere amplified in triplicate using primers for murine
endogenous control Hprt or primers for murine Sgpp1, Siat9, Nr3c1,
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Runx1 (Qiagen QuantiTect Primer Assays) or Ugcg (779F 50
tttgctcagtacattgctgaagatta30 and861R50 acttgagtagacattgaaaacctccaa
30). Relative quantification was carried out and calibrated to vector
control samples (18).
LENTIVIRUS PRODUCTION AND GENE KNOCKDOWN
SMARTvector 2.0 lentiviral shSgpp1 and shNC non-coding control
particleswerepurchased fromThermoScientific (2 108particles/ml).
shGAPDH lentiviral particles were included as a positive control for
transduction efficiency. Virus supernatants were thawed on the day of
transfection and centrifuged onto retronectin-coated plates at 3220g
for 1 h at 4°C (4 105 particles/well of a 24-well plate). Supernatants
were aspirated from the plates and replaced with fresh supernatant
(2 105 particles/well) and spun as before. The 105 cells were added in
an equal volume per well and incubated for 7 h with 8mg/ml
polybrene. The medium was replaced with fresh medium overnight
and then removed.A second infectionwith2 105virus particles in an
equal volume of fresh medium containing 8mg/ml polybrene was
performed for a further 7 h before the cells were dissociated from the
retronectin and incubated in fresh medium. After 40h, the medium
was replaced with media containing 2mg/ml puromycin to allow for
selection of virally transduced cells. For qt-RT-PCR and viability
counts, puromycin-resistant cells were plated as described in the
presence and absence of 1.0mM dexamethasone.
MASS SPECTROMETRY: CERAMIDE AND S1P EXTRACTION AND
ANALYSIS FROM CELLS
Ceramide and S1P extraction was performed with a modified Folch
approach. Briefly, cells from pellets or pulverized tissues were washed
twice with cold PBS and re-suspended in 1.5ml methanol. After
addition of 50ng C17-ceramide and 15ng C17-S1P as internal
standards, 1.5ml of 0.88% NaCl and 3ml chloroform were added, the
mixture vortexed for 20 s and sonicated for 2min. Then the sample was
centrifuged at 1000g at 4C for 15mins. The lower phase was collected.
The upper phase was re-extracted with 3ml synthetic lower phase (mix
chloroform/methanol/0.88% NaCl at volume ratio of 2:1:1, after phase
separation, take the lower phase as synthetic lower phase). The lower
phases were combined, dried with SpeedVac (Thermo) and re-dissolved
in 60ml chloroform.A total of 7ml were injected for LCMS/MSanalysis.
Another 7ml of sample was used for S1P analysis as described below
with 4000QTRAP (AB Sciex). For LC/MS/MS analysis of ceramide, a
Thermo Orbitrap Elite system (Thermo Fisher) was hyphenated with a
five-channel online degasser, four-pump, column oven, and autosam-
plerwith cooler Shimadzu Prominence HPLC system. Lipid classes were
separated on a normal phase silica gel column (2.1 150mm, 4micro,
MicoSolv Technology) with hexane/dichloromethane/chloroform/
methanol/acetanitrile/water/ethylamine solvent gradient based on
the polarity of head group. High resolution (240k at m/z 400)/accurate
mass (withmassaccuracy<5ppm)and tandemMS(CID fragmentation)
were used for molecular species identification and quantification and
further confirmed by reference to appropriate lipids standards. Orbitrap
Elite mass spectrometer operation conditions: for ceramide analysis,
heated ESI Source in negative ESI mode, heater temperature: 325°C,
sheath gasflow rate (arb): 45, auxgasflow rate (arb): 10, sweepgasflow
rate (arb): 0, I spray voltage: 3.0 kV, capillary temperature: 375°C, S-
Lens RF level: 70%. Orbitrap mass analyzer was operated as SIM scan
modewithmass range:m/z 510–740,mass resolution: 240katm/z 400.
Ion trap mass analyzer was operated as dependent scan in CID mode at
normal scan speed.
MASS SPECTROMETRY: S1P EXTRACTION AND ANALYSIS FROM
CELL CULTURE MEDIA
A total of 800ml cell culture media, 200ml 0.88% NaCl, and 2ml
n-butanol were mixed in pre-cleaned 1.5ml Eppendorf tubes,
with 15 ng C17-S1P as internal standard. After vortexing for 20 s
at room temperature and sonication in an ice-cold water bath for
3min, the tubes were centrifuged at 1500g 4°C for 10min
collecting the upper organic phase. The lower phase was re-
extracted with 2 ml n-butanol and the organic extractions
combined. The lipid extract was dried under vacuum at room
temperature with SpeedVac (Thermo), re-dissolved in 60ml
chloroform/methanol/water 2:5:1 (v/v/v) solvent mixture. A
total of 7ml were injected onto a Gemini—NX—3u C18
2.0 150mm column (Phenomenex) for LC-MS/MS analysis of
S1P with Shimadzu Prominence HPLC system hyphenated with
AB Sciex 4000 QTRAP mass spectrometer. The S1P separation
was carried out with a binary gradient elution at flow rate of
0.25ml/min with column oven set at 25°C. Mobile phase A: 5%
acetonitrile with 1% formic acid and 5mM ammonium formate;
Mobile phase B: 95% acetonitrile with 1% formic acid and 5mM
ammonium formate. The gradient was run from 10% B to 100% B
in 10min. A total of 4000 QTRAP mass spectrometer source/gas
parameters: curtain gas: 25; collision gas: high; ionspray
voltage: 4500; temperature: 550; ion source gas 1: 30; ion
source gas 2: 45; interface heater: on. The following Compound
Parameters were used for Multiple Reaction Monitoring (MRM)
analysis of each molecular species of S1P. Both Q1 and Q3 mass
were set up at unit resolution (Table I).
WESTERN BLOTTING AND ANTIBODIES
Preparation of whole cell protein extracts was performed as described
previously (21). Samples equivalent to30mgofprotein (Bio-Radprotein
TABLE I. Compound Parameters for Multiple Reaction Monitoring
Compound
Q1 mass
(Da)
Q3 mass
(Da)
Declustering potential
(DP)
Entrance potential
(EP)
Collision energy
(CE)
Collision cell exit potential
(CXP)
C16-S1P 350.2 78.9 90 10 48 5
C17-S1P 364.2 78.9 90 10 48 5
C18:1-S1P 376.2 78.9 95 8 62 5
C18-S1P 378.2 78.9 95 8 62 5
C20-S1P 406.3 78.9 95 8 62 5
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assay) were resolved on 8%SDS polyacrylamide gels and transferred to
enhanced chemiluminescence nitrocellulose membranes (ECL; Amer-
sham, Little Chalfont, UK). The antibodies used were a Runx1 #8229
(Cell Signalling Technologies) and a actin sc1616 (Santa Cruz).
STATISTICAL ANALYSIS
Graphs were generated with Excel as mean values and error bars
relate to standard deviations. All statistical comparisons were
performed using the Student’s t test. Unless stated a significance
value¼<0.05 is denoted by () and of¼<0.01 by ().
RESULTS
Runx1 PROMOTES S1P RELEASE FROM LYMPHOMA CELLS
We previously reported that ectopic Runx1 depletes intracellular
long chain ceramides and opposes ceramide-induced apoptosis in
murine fibroblasts [Kilbey et al., 2010]. To determine whether the
sphingolipid rheostat is similarly perturbed in a context where
Runx1 has established in vivo oncogenic function [Blyth et al., 2001;
Shimizu et al., 2013], we introduced Runx1 into two independently
derived p53-null T cell lymphoma lines (Fig. 1A). Vector-driven
expression led to increased levels of Runx1 protein at 4.3- and
4.5-fold over the endogenous levels in p/m97 and p53/184 cells,
respectively (Fig. 1B). Mass spectrometric analysis of ceramide/S1P
revealed modest but consistent reductions in the levels of the most
abundantly expressed long chain intracellular ceramides (16.0, 24.1,
and 24.0-Cer) in the presence of ectopic Runx1 (Fig. 1C—solid bars
P¼<0.01). The remaining ceramides (14.0, 16.1, 18.0, 20.0, 22.1,
24.2-Cer; Fig. 1C—hashed bars) were detected at much lower levels
but a significant reduction was preserved when these were included
in the total (P¼<0.01). A more dramatic effect was observed on
extracellular C18-S1P which was induced three to fivefold in the
presence of ectopic Runx1 (Fig. 1D). The level of induction was
further stimulated by serum (FCS) to activate sphingosine kinase and
the conversion of sphingosine to S1P. Indeed by 15min, serum-
induced levels of C18-S1P in the presence of ectopic Runx1 (pink
bar) exceeded the sum of ectopic Runx1 (red bar) or FCS (gray bar)
alone suggesting that ectopic Runx1 and FCS have additive effects in
T lymphoma cells and that absolute levels of Runx1 modulate
C18-S1P production in vitro.
ENFORCED DELETION OF Runx1 IMPAIRS S1P RELEASE IN VIVO
To determine whether Runx1 plays an essential physiological role in
sphingolipid metabolism in vivo we attempted to delete Runx1 in
otherwise genetically normal Runx1fl/flMx1Creþ conditional knock-
outmice.A previouslyvalidated direct PCR assaywas used tomeasure
the proportion of excised to non-excised allele in the tissue [Borland
et al., 2016]. As reported, most normal mouse tissues resist enforced
deletion of Runx1 [Tober et al., 2013], suggesting that this gene plays
anessentialmaintenance role inmanymature cell types.Nevertheless,
we were able to achieve partial Runx1 ablation in spleen tissues
from 60-day-old Runx1fl/flMx1Creþ transgenic animals where pIpC
induction of Cre recombinase led to Runx1 excision rates of
50–55%. Background excision in Mx1Creþ mice treated with PBS
alone was in the order of 40% presumably due to endogenous
interferon activity (Fig. 2A). Runx1 transcript levels as measured by
qt-RT-PCR closely paralleled DNA excision rates in Mx1Creþ spleens
(pale green vs. dark green bars) and were significantly different from
control Runx1fl/fl mice lacking Mx1Cre that showed no response to
pIpC treatment (Fig. 2B; gray vs. black bars). Despite these substantial
excision rates, Runx1-excised mice showed surprisingly little
perturbation in spleen cell populations [Borland et al., 2016]. Parallel
tissue sampleswere processed for biochemical analysis of C18-S1P by
mass spectrometry and revealed a strong correlation between loss of
Runx1 and C18-S1P in vivo (Fig. 2C). Splenic tissue levels of C18-S1P
weremoderately reduced by background excision alone (gray bars vs.
pale green bars), but significant depletion was observed in the
presence of pIpC (black bars vs. dark green bars). To control for non-
specific effects of the Cre recombinase spleen tissue samples were
prepared from Runx1wt/wt—Mx1Creþ and Runx1wt/wt—Mx1Cre
transgenic mice treated with and without pIpC as described
previously. In this case, no significant differences in C18-S1P were
recorded between the different experimental groups (data not shown),
suggesting that loss ofRunx1was responsible for the reduced levels of
C18-S1P in pIpC-treated Runx1fl/flMx1Creþ mice.
Fig. 1. Ectopic Runx1 promotes S1P release from T-lymphoma cells. (A) Total
protein was extracted from p/m97 or p53/184 thymic lymphoma cells
transduced with the pBabeRunx1 retroviral vector or the pBabePuro vector
control and probed against antibodies to Runx1 (Cell Signalling #8229) or
actin (Santa Cruz sc-1616) as a loading control. Lymphoma cells over-
expressing Runx1 (9) were included as a positive control. (B) The blot was
quantified using image J software and the Runx1 fold change indicated below
the histogram. (C) Long chain ceramides were extracted from cell pellets from
pBabePuro vector control and pBabeRunx1-expressing T lymphoma cells
(p/m97 shown), and separated, identified, and semi-quantitated by HPLC mass
spectrometry. The data are means SD where n¼ 4 from one experiment
typical of two. Solid bars represent combined levels of 16.0, 24.1, and 24.0-Cer
(P¼<0.01). A significant difference between ectopic Runx1 expressing and
non-expressing cells was preserved when the remaining ceramides (14.0, 16.1,
18.0, 20.0, 22.1, 24.2-Cer—displayed in hashed bars) were included in the total
(P¼<0.01). (D) C18-S1Pwas analyzed from conditionedmedia collected from
pBabePuro vector control and pBabeRunx1-expressing T lymphoma cells by
HPLC mass spectrometry (p/m97 shown). FCS was included to activate Sphk1.
The data are means SD where n¼ 4 from one experiment typical of two.
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Runx1 PROTECTS LYMPHOMA CELLS AGAINST DEXAMETHASONE-
INDUCED APOPTOSIS
We previously reported that each of the three Runx genes can oppose
dexamethasone-induced growth inhibition in murine fibroblasts, at
least in part by down-regulation of the glucocorticoid receptor gene,
Nr3c1 [Wotton et al., 2008]. We tested this observation further in
lymphoid cells where dexamethasone induces apoptosis rather than
growth stasis and glucocorticoids feature as important therapeutic
agents in lymphoma treatment [Bhadri et al., 2012]. Using trypan
blue exclusion as a surrogate for viability, ectopic Runx1 was
observed to provide a sustained protective effect against dexameth-
asone that increased markedly from 48 h after dexamethasone
exposure (Fig. 3A). The protective effect was even more striking in
light of themodest growth inhibition observedwith ectopic Runx1 in
this cell background (Fig. 3B). Together these data suggest that
protection against dexamethasone-induced death is due to increased
survival mediated by Runx1. Modulation of pro- and anti-apoptotic
enzyme expression to promote apoptosis was previously reported in
response to dexamethasone in double positive murine thymocytes
[Bianchini et al., 2006]. Of these, Sgpp1 and Ugcg were also
identified as direct transcriptional targets of Runx1 in
murine fibroblasts, whereas the glucocorticoid receptor Nr3c1
was identified as an indirect target [Wotton et al., 2008;
Kilbey et al., 2010]. To determine whether Runx1 opposed
dexamethasone-mediated gene expression to promote cell survival
we examined transcription of Runx1, Sgpp1, Ugcg, and Nr3c1 by
qt-RT-PCR in the presence and absence of dexamethasone and
ectopic Runx1. As shown in Figure 3C, endogenous Runx1 was
repressed by dexamethasone as previously reported, but the
pattern was reversed in the presence of ectopic Runx1. In contrast,
Sgpp1 expression was dramatically opposed by ectopic Runx1 in
dexamethasone-treated p/m97 cells whereas Nr3c1 expression was
not. Indeed, as previously reported in murine fibroblasts, Nr3c1
was slightly downregulated by ectopic Runx1 but was upregulated
by dexamethasone in both the presence and absence of ectopic
Runx1 [Wotton et al., 2008]. Ugcg expression was refractory to
dexamethasone treatment in p53-null thymic lymphoma cells but
was induced by Runx1. This finding contrasts with double positive
murine thymocytes where Ugcg was reportedly repressed by
dexamethasone [Bianchini et al., 2006] but was consistent with the
effects of ectopic Runx1 on Ugcg transcription in murine
fibroblasts [Wotton et al., 2008; Kilbey et al., 2010]. Together
the data support a mechanism whereby the opposition of Sgpp1
transcription and the overexpression of Ugcg might contribute to
Runx1-induced survival in the presence of dexamethasone in
thymic lymphoma cell lines.
Fig. 2. Enforced deletion of Runx1 impairs S1P release in vivo. (A) PCR genotyping of 60-day-old splenic tissue DNA from Runx1fl/flMx1Creþmice treated with vehicle control
(PBS) for background excision or pIpC to excise Runx1. Samples: A–C, 60-day spleen tissue samples from two groups of three Runx1fl/flMx1Creþmice treated with either PBS or
pIpC; D–F DNA controls, non-excised Runx1fl/flMx1Cre (D), a mixture of partially excised Runx1fl/flMx1Creþ and Balb/c normal kidney to show all three possible PCR products
(E) and Balb/c normal kidney (F). Positions of Floxed (Runx1Fl), deleted (DRunx1Fl), and wildtype (WT) Runx1 alleles are as shown. Quantitation to estimate relative excision was
performed using image J software. Estimated background and pIpC excision rates are labeled under the blots. (B) qt-RT-PCR analysis of Runx1 expression in 60-day splenic tissue
RNA samples from Runx1fl/flMx1Creþ mice treated with vehicle control or pIpC (dark and light green bars, respectively). Parallel samples were analyzed from Runx1fl/fl mice
lacking theMx1Cre gene to control for PBS and pIpC treatment (black and gray bars, respectively). The data are means SDwhere n¼ 9 representing three technical replicates of
each biological replicate (3). A significant reduction in Runx1 expression was observed betweenMx1Creþ andMx1Cremice indicating background excision (gray vs. light green
bar; P¼<0.05). Inclusion of pIpC to excise Runx1 generated a further reduction (black vs. green bar; P¼<0.01). (C) Remaining splenic tissues were pulverized and analyzed by
HPLCmass spectrometry for C18-S1P. Data are expressed relative to 1mg of pulverized spleen tissue and represent means SD of spleens of threemice for each set of conditions.
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Runx1 EXCISION PROMOTES DEXAMETHASONE-INDUCED
APOPTOSIS AND Sgpp1 TRANSCRIPTION
To further explore the relationship between Runx1 and Sgpp1
in dexamethasone-induced apoptosis, we examined Runx1fl/fl/
Mx1Creþ B cell lymphoma lines established from a mouse model
heterozygous for p53 loss and expressing c-Myc in the B cell
compartment (Em-Myc). We exploited interferon b induction of
Mx1Cre to mediate in vitro excision of Runx1 and derived a pair of
clonally identical daughter cell lines that express low but readily
detectable levels of full length Runx1 (Runx1Fl) or the deleted non-
functional variant (DRunx1Fl—Fig. 4A) and asked whether loss of
Runx1 promotes dexamethasone-induced apoptosis and Sgpp1
transcription. Enforced deletion of endogenous Runx1 significantly
increased cell death in response to 1.0mM dexamethasone (Fig. 4B).
Moreover, enforced deletion ofRunx1 increased expression of Sgpp1
in DRunx1Fl cells (black vs. green bars) and this was further
increased in the presence of dexamethasone (hashed black vs. green
bars) (Fig. 4C). Parallel cell lines derived from Runx1wt/wt/Mx1Creþ/
p53+//Em-Myc lymphomas were refractory to interferon b with
respect to Sgpp1 and Runx1 expression [Borland et al., 2016] thereby
excluding a non-specific effect of the Mx1Cre recombinase as a
causative factor for the increase in Sgpp1 expression following
Runx1 excision. To determine which functional domains of Runx1
are required to suppress Sgpp1 induction in the presence of
dexamethasone, we introduced a panel of Runx1 mutants (Fig. 4D)
into DRunx1Fl cells which essentially lack Runx1 expression.
qt-RT-PCR analysis revealed that Runx1 repression of Sgpp1 was
dependent on intact DNA binding and heterodimerization domains
(Fig. 4D), indicating that Runx1 directly opposes dexamethasone-
induced transcription of Sgpp1.
Sgpp1 KNOCKDOWN REDUCES DEXAMETHASONE-INDUCED CELL
DEATH
To investigate the role of Sgpp1 as a direct mediator of glucocorticoid-
mediated apoptosis we used a short hairpin (sh) RNA to knock down
expression of Sgpp1 in p/m97 thymic lymphoma cells which displayed
the most dramatic induction of Sgpp1 in response to dexamethasone
(Fig. 3C—black bar vs. hashed black bar). Retroviral transduction of
Sgpp1 shRNA viral supernatants reduced dexamethasone-induced
expression of Sgpp1 by 40% compared to the non-coding (NC)
shRNA control sequences (Fig. 5A). Stably transduced cells were then
cultured in the presence and absence of dexamethasone and cell death
measured by trypan blue exclusion. After 36hr, dexamethasone-
induced death was reduced by 20% in cells receiving Sgpp1 shRNA
compared to the NC shRNA control sequence (Fig. 5B). Together these
data indicate that Sgpp1 induction is at least partially responsible for
death of lymphomacellsmediated by glucocorticoid signaling. Insights
gained from this data regarding the interplay between dexamethasone
and Runx1 for the regulation of sphingolipid metabolism and cell
survival are illustrated in the model shown in Figure 5C.
DISCUSSION
Previous studies in murine fibroblasts identified three sphingolipid
metabolism enzymes as direct transcriptional targets of the three
Fig. 3. Runx1 protects lymphoma cells against dexamethasone-mediated apoptosis. (A) p53 null lymphoma cells transduced with the pBabeRunx1 retroviral vector or the
pBabePuro vector control (p/m97 shown) were plated in triplicate in the presence and absence of 1.0mM dexamethasone and monitored for live/dead counts by trypan blue
exclusion over 4 days. (B) The same cells were plated at 4 105 per well in triplicate wells of a 12-well plate and monitored for growth over 48 h. Ectopic Runx1 significantly
reduced cell proliferation at 24 h (P< 0.01), 40 h (P< 0.01), and 48 h (P< 0.01). (C) qt-RT-PCR analysis of Runx1, Sgpp1, Ugcg, and Nr3c1 in pBabePuro vector control and
pBabeRunx1-expressing T lymphoma cells (p/m97 shown) grown in the presence and absence of 1.0mM dexamethasone for 6 h. The data are means SD where n¼ 9
representing three technical replicates of each biological replicate (3) from one experiment typical of two.
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members of the Runx gene family [Wotton et al., 2008; Kilbey et al.,
2010]. Moreover, the pronounced pro-survival effects of ectopic
Runx expression in this context were associated with depletion of
intracellular ceramide levels suggesting a shift in the sphingolipid
rheostat in favor of pro-survival S1P [Kilbey et al., 2010]. We have
now extended these studies to the lymphoid system where ectopic
Runx expression has been shown to be potently oncogenic in
combination with other cancer gene lesions including p53 loss and
Myc over-expression [Vaillant et al., 1999; Blyth et al., 2001, 2006;
Shimizu et al., 2013]. In thymic lymphoma cells Runx1 expression
consistently regulates sphingolipid metabolism to favor S1P
production with concomitant reduction in long chain ceramides.
As we found, no positive effect of Runx1 over-expression on cell
proliferation in this cell background, these results strongly reinforce
previous evidence for enhanced survival as a key mechanism in
Runx oncogenesis [Blyth et al., 2006]. Moreover, we have shown that
partial deletion of Runx1 in vivo results in a significant and specific
reduction in tissue S1P levels, revealing a fundamental physiological
role for Runx regulation of sphingolipid metabolism in normal
hematopoiesis. The production and distribution of S1P in spleen is
known to be tightly regulated [Ramos-Perez et al., 2015] and the
importance of Runx1 expression for maintenance of S1P levels
described here is likely to be critical for regulation of the immune
system.
The regulation of sphingolipid metabolism by the Runx genes is a
multigenic phenomenon involving both direct and indirect gene
regulation and entails a series of incremental changes in individual
genes that combine to achieve significant metabolic shifts [Wotton
et al., 2008; Kilbey et al., 2010]. However, this study highlights an
additional need to measure transcriptomic changes under stress if
the consequences of Runx modulation for sphingolipid metabolism
are to be fully understood. In particular, ectopic Runx1 significantly
impaired the massive induction of Sgpp1 in T-lymphoma cells in
response to dexamethasone, but had no effect on basal expression of
the gene in these cells. Similarly, although Sgpp1 was up-regulated
in response to deletion of Runx1 in B-lymphoma cells, the
differential was more marked in the presence of dexamethasone.
Replacement with ectopic Runx1 reversed this effect, but not when
the DNA or Cbfb cofactor binding functions were disabled,
indicating that suppression most likely operates through the
previously mapped binding site in the Sgpp1 promoter [Kilbey
et al., 2010].
Dexamethasone is a synthetic glucocorticoid that induces
ceramide and sphingosine to promote apoptosis in mouse thymo-
cytes in a manner that mimics the normal process of T cell selection
in the thymus [Cifone et al., 1999; Lepine et al., 2004]. Previous
studies in primary mouse thymocytes identified changes in Runx1,
Nr3c1, Ugcg, and Sgpp1 as early consequences of dexamethasone
Fig. 4. Enforced deletion of Runx1 promotes dexamethasone-mediated apoptosis and Sgpp1 transcription. (A)Western blotting analysis as described in Figure 1A to detect the
deleted (DRunx1Fl) and full length (Runx1Fl) Runx1 proteins from in vitro excised in Runx1fl/flMx1Creþ 3s B lymphoma cells. (B) Paired cell lines expressing the deleted
(DRunx1Fl) and full length (Runx1Fl) proteins after in vitro excision of Runx1fl/flMx1Creþ 3s B lymphoma cells were plated in triplicate in the presence of 1.0mMdexamethasone
and monitored for live/dead counts by trypan blue exclusion. (C) qt-RT-PCR analysis of steady state levels of Sgpp1 in DRunx1Fl and Runx1Fl 3s cells grown in the presence and
absence of 1.0mM dexamethasone for 6 h. The data are means SD where n¼ 9 representing three technical replicates of each biological replicate (3) from one experiment
typical of two. (D) Runx1 schematic showing themutated residues in the heterodimerization (T161A) and DNA-binding (K83N) domains. qt-RT-PCR analysis of Sgpp1 expression
in DRunx1Fl 3s cells transfected with full length Runx1, T161A Runx1, or K83N Runx1. Absolute levels of Sgpp1 were compared to control cultures expressing the pBabe Puro
vector alone. The data were compiled as described in (C).
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treatment compatible with ceramide-induced apoptosis [Bianchini
et al., 2006]. Our studies in lymphoma cells partially recapitulate
thesefindings, and indicate a causal chain inwhich down-regulation
of Runx1 is proximal to the other changes and reversed by ectopic
expression. Moreover, we have identified positive regulation of Ugcg
and repression of Sgpp1 as consistent Runx1 functions. An effector
role for Sgpp1 in the depletion of S1P and concomitant
dexamethasone-induced death is further supported by shRNA knock
down of Sgpp1 which, although far from complete, showed a
significant sparing effect.
The importance of S1P for survival and drug resistance has been
well documented in hematological malignancies but is more
commonly attributed to deregulation of Sphk1 or Ugcg rather
than to reduced levels of Sgpp1 [Marfe et al., 2011; Casson et al.,
2013]. However, the fundamental importance of Sgpp1 is underlined
by the neonatal lethality of gene deletion in mice [Allende et al.,
2013] and the effects of modulating expression on cell growth and
survival in response to cellular stress. For example, depletion of
Sgpp1 promotes ER stress-induced autophagy in eukaryotic cell lines
[Lepine et al., 2011] and thermo tolerance in yeast [Mao et al., 1999],
whereas ectopic expression of Sgpp1 promotes apoptosis and
accumulation of intracellular ceramide in NIH3T3 and HEK293
fibroblasts [Le Stunff et al., 2002]. The relevance of SGPP1 in other
cancer types is suggested by its down-regulation in therapy-resistant
ovarian and prostate cancers [Helleman et al., 2006; Huang et al.,
2013].
The observation that ectopic Runx1 suppresses glucocorticoid-
induced death and that deletion of endogenousRunx1has the opposite
effect also helps to elucidate the oncogenic consequences of Runx
over-expression in lymphoid cells [Stewart et al., 1997, 2002; Wotton
et al., 2002]. Moreover, glucocorticoids comprise key components of
multi-drug regimens for the treatment of acute lymphoid malignan-
cies, where resistance is common but the underlying in vivo
mechanisms poorly understood [Bhadri et al., 2012]. Our results
predict that perturbations in expression of RUNX family members in
human leukemia will be relevant to cell survival and therapy
resistance. In support of this hypothesis, human t(8;21) leukemias
that carry only a single functional RUNX1 allele are unique among
AMLs in their sensitivity to glucocorticoids [Miyoshi et al., 1997].
Moreover, relapsing t(12;21) leukemias harboring the TEL-RUNX1
fusion displaymutually exclusive gains of extra wild-type RUNX1 on
chromosome 21 and losses of the glucocorticoid receptor Nr3c1. In
light of these and our observations reported here it will therefore be
interesting to test the synergistic potential of glucocorticoids and
Fig. 5. shRNA knockdown of Sgpp1 reduces dexamethasone-mediated apoptosis. (A) qt-RT-PCR analysis of Sgpp1 expression in p/m97 cells stably infected with viral
supernatants expressing an Sgpp1 or a non-coding (NC) control shRNA sequence. Cells were grown for 6 h in the presence of 1.0mMdexamethasone prior to RNA extraction and
qt-RT-PCR analysis. The data were calculated as described in Fig. 4C. (B) The same cells were plated in triplicate and grown for 36 h in the presence (Dex) and absence (MtOH) of
1.0mM dexamethasone and monitored for live/dead counts by trypan blue exclusion. Knockdown of Sgpp1 had no effect on cell viability under control conditions but gave a
significant reduction in cell death in the presence of 1.0mM dexamethasone. (C) Interplay between Runx1 and dexamethasone on the expression of sphingolipid metabolism
enzymes involved in the synthesis and breakdown of sphingosine and ceramide and their potential contributions to cell death and survival [Bianchini et al., 2006; Kilbey et al.,
2010].
JOURNAL OF CELLULAR BIOCHEMISTRY Runx1 LINKS SPHINGOLIPIDS TO SURVIVAL IN LYMPHOMA 1439
inhibi tors ofRUNX-CBFb functions [Illendula et al., 2016] or their key
downstream targets in sphingolipid metabolism [Edmonds et al.,
2011] in the growing number of cancers where the RUNX genes are
implicated as oncogenic drivers [Ito et al., 2015].
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